D467 Thames Ventures Vct 2 Plc

 
TIDMD467 
 
   Downing FOUR VCT plc (the "Company") 
 
   LEI: 21380035MV1VRYEXPR95 
 
   7 June 2021 
 
   Portfolio Update (Correction) 
 
   The announcement issued by the Company on 3 June 2021 at 15:47 contained 
an error in respect of the increase in value of the Company's holdings 
in Arecor Therapeutics plc on its admission to AIM. The correct figures 
for the increase in value of the Company's holdings were 0.7p per 
Generalist Share and 6.3p per Healthcare Share (not 0.9p and 8.0p as 
originally stated). This equates to increases of 1.0% and 9.0% in the 
NAV of the Generalist Shares and Healthcare Shares (not 1.3% and 11.4% 
as originally stated). 
 
   The full corrected text of the 3 June 2021 announcement is as follows: 
 
   The Directors of the Company are pleased to report that Generalist and 
Healthcare Share portfolio company, Arecor Therapeutics ("Arecor"), has 
today (3 June 2021) had its ordinary shares admitted to trading on AIM. 
The admission follows a successful GBP20.0 million placing of new shares 
at a price of 226 pence per ordinary share (the "placing price"). 
 
   Based on the placing price, the values of the Company's Generalist and 
Healthcare Share pools' holdings in Arecor have increased by 
approximately 0.7p per Generalist Share and 6.3p per Healthcare Share 
(based on shares in issue at 28 February 2021, being the date of the 
latest NAVs announced by the Company). This is equivalent to increases 
of 1.0% and 9.0% in the unaudited NAVs of the Generalist and Healthcare 
Share pools respectively, as at 28 February 2021. 
 
   Enquiries: 
 
   Grant Whitehouse 
 
   Downing LLP 
 
   Company Secretary 
 
   020 7630 4333 
 
 
 
 
 
 

(END) Dow Jones Newswires

June 07, 2021 12:06 ET (16:06 GMT)

Thames Ventures Vct 2 (LSE:D467)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Thames Ventures Vct 2 (LSE:D467)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024